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Folic acid handling by the human gut: implications for food fortification
and supplementation1–3
Imran Patanwala, Maria J King, David A Barrett, John Rose, Ralph Jackson, Mark Hudson, Mark Philo, Jack R Dainty,
Anthony JA Wright, Paul M Finglas, and David E Jones
ABSTRACT
Background: Current thinking, which is based mainly on rodent
studies, is that physiologic doses of folic acid (pterylmonoglutamic
acid), such as dietary vitamin folates, are biotransformed in the
intestinal mucosa and transferred to the portal vein as the natural
circulating plasma folate, 5-methyltetrahydrofolic acid (5-MTHF)
before entering the liver and the wider systemic blood supply.
Objective: We tested the assumption that, in humans, folic acid is
biotransformed (reduced and methylated) to 5-MTHF in the intes-
tinal mucosa.
Design: We conducted a crossover study in which we sampled
portal and peripheral veins for labeled folate concentrations after
oral ingestion with physiologic doses of stable-isotope–labeled
folic acid or the reduced folate 5-formyltetrahydrofolic acid (5-
FormylTHF) in 6 subjects with a transjugular intrahepatic porto
systemic shunt (TIPSS) in situ. The TIPSS allowed blood samples
to be taken from the portal vein.
Results: Fifteen minutes after a dose of folic acid, 80 6 12% of
labeled folate in the hepatic portal vein was unmodified folic acid.
In contrast, after a dose of labeled 5-FormylTHF, only 4 6 18% of
labeled folate in the portal vein was unmodified 5-FormylTHF, and
the rest had been converted to 5-MTHF after 15 min (postdose).
Conclusions: The human gut appears to have a very efficient ca-
pacity to convert reduced dietary folates to 5-MTHF but limited
ability to reduce folic acid. Therefore, large amounts of unmodified
folic acid in the portal vein are probably attributable to an extremely
limited mucosal cell dihydrofolate reductase (DHFR) capacity that
is necessary to produce tetrahydrofolic acid before sequential meth-
ylation to 5-MTHF. This process would suggest that humans are
reliant on the liver for folic acid reduction even though it has a low
and highly variable DHFR activity. Therefore, chronic liver expo-
sure to folic acid in humans may induce saturation, which would
possibly explain reports of systemic circulation of unmetabolized
folic acid. This trial was registered at clinicaltrials.gov as
NCT02135393. Am J Clin Nutr 2014;100:593–9.
INTRODUCTION
Naturally occurring dietary folates are a group of water soluble
polyglutamate tetrahydrofolate B vitamins (mainly methylte-
trahydrofolates and formyltetrahydrofolates) that are vital single
carbon donors in human metabolism. A low folate status has been
associated with adverse health outcomes. In pregnancy, it is
unambiguously associated with increased risk of fetal neural tube
defects that can be reduced by periconceptual folic acid sup-
plementation (1). A low folate status has also been associated
with elevated plasma homocysteine, which has been a suggested
risk factor for cardiovascular disease, stroke, and dementia (2–4),
and altered DNA methylation and uracil-induced genomic in-
stability, which may increase risk of colorectal cancer in theory
(5) but perhaps not in practice (6). Therefore, an optimal dietary
intake of folate is important. An alternative approach, which would
give universal benefit, is to fortify food with folic acid. A number
of countries, including the United States, Canada, and Chile already
have mandatory programs of folic acid fortification of flour (7).
Concerns have been mounting about the safety of a persistent
exposure to folic acid that results in the circulation of unmetabolized
folic acid (8), including the potential for masking vitamin B-12
deficiency (9) and the acceleration of cognitive decline in the elderly
with a low vitamin B-12 status (10, 11). An increase in the incidence
of prostate and other cancers was seen in studies performed to
address the hypothesis that folic acid supplementation reduces
cancer risk, and an increase in overall mortality was seen in patients
who were taking folic acid supplements (12–15).
That dietary folate is beneficial but supplemental folic acid may
have some detrimental effects is a paradox because both dietary
folates and folic acid are taken up by mucosal cells with a similar
affinity by the proton-coupled folate transporter (16), and the
absorptive mucosa simply rearranges 5-formyltetrahydrofolic acid
(5-FormylTHF)4 to 5-methyltetrahydrofolic acid (5-MTHF) be-
fore transport to the serosal side (17) and transports 5-MTHF
1 From the Institute of Cellular Medicine, Newcastle University, Newcastle
upon Tyne, United Kingdom (IP, MH, and DEJ); the Institute of Food Re-
search, Norwich Research Park, Norwich, United Kingdom (MJK, MP, JRD,
AJAW, and PMF); the Centre for Analytical Bioscience, School of Phar-
macy, University of Nottingham, Nottingham, United Kingdom (DAB); and
the Department of Radiology, Freeman Hospital, Newcastle upon Tyne,
United Kingdom (JR and RJ).
2 Supported by the UK Biotechnology and Biological Sciences Research
Council (grants BB/F014104/1 and BB/FO14457/1). This is an open access
article distributed under the CC-BY license (http://creativecommons.org/
licenses/by/3.0/).
3 Address correspondence to DE Jones, Institute of Cellular Medicine,
Fourth Floor, William Leech Building, Medical School, Framlington Place, New-
castle upon Tyne NE20 0SU, United Kingdom. E-mail: david.jones@ncl.ac.uk.
4 Abbreviations used: DHFR, dihydrofolate reductase; TIPSS, transjugular
intrahepatic porto systemic shunt; 5-FormylTHF, 5-formyltetrahydrofolic
acid; 5-MTHF, 5-methyltetrahydrofolic acid.
ReceivedNovember 21, 2013. Accepted for publication May 12, 2014.
First published online June 18, 2014; doi: 10.3945/ajcn.113.080507.
Am J Clin Nutr 2014;100:593–9. Printed in USA. 593
 at N
ew
castle University on O
ctober 8, 2014
ajcn.nutrition.org
D
ow
nloaded from
 
unchanged. The generally accepted wisdom (derived from rodent
studies) is that physiologic doses of folic acid are biotransformed
in the intestinal absorptive mucosa and transferred to the hepatic
portal vein as 5-MTHF in the same way as dietary folates (18–
20). That this process may also be applicable to humans may have
been a misreading of an article that concluded “under physio-
logical conditions only 5-MTHF reaches the blood.” However,
the article referred to a study where only a small percentage of
ingested folate was folic acid (21). This apparent consensus was
challenged by studies that showed a significantly different sys-
temic plasma (labeled) 5-MTHF appearance after the ingestion of
single, physiologic doses of stable-isotope–labeled vitamin folates
and folic acid (22).
The aim of the current study was to identify the site of
biotransformation of folic acid in humans by sampling portal
venous blood from subjects with a transjugular intrahepatic
porto systemic shunt (TIPSS) in situ who were exposed to orally
ingested labeled folic acid or a physiologic dietary folate (for-
myltetrahydrofolic acid).
SUBJECTS AND METHODS
Study design
In the current study, we used an opportunity offered by subjects
with an in situ TIPSS to directly investigate the metabolic
processing of folic acid and other folates by the intestinal tract.
All subjects were in a program of follow-up monitoring and had
stable liver cirrhosis. The physical location of the TIPSS (Figure
1) allows safe blood sampling from the hepatic portal vein,
thereby providing a unique insight into the metabolic fate of
folates immediately after passing through mucosal cells.
To be eligible for the study, participants had to have stable,
synthetic liver function without recent evidence of decompensation
(defined as liver-function inadequacy or active complications of
portal hypertension), be abstinent from alcohol, be free from
malignant disease, have normal gut permeability as evidenced
by the recovery of urinary lactulose and mannitol after an oral
test dose in the reference range, and have a patent TIPSS on their
last surveillance. Participants who were receiving folic acid
supplementation or taking vitamin B supplements were ex-
cluded. Six subjects who had undergone a TIPSS insertion at the
Freeman Hospital, Newcastle on Tyne, United Kingdom, be-
tween 1992 and 2009 provided written, informed consent to take
part in the study. All studies were conducted according to the
guidelines laid down in the Declaration of Helsinki, and all
procedures involving human subjects were approved by the
Newcastle and North Tyneside 1 Research Ethics Committee
(08/H0906/82). The small sample size was a consequence of the
number of patients who were eligible in the hospital database
(n = 26). Of these subjects, 17 patients did not return their
expression of interest letter after one reminder. Of the other 9
subjects, one patients did not consent, one patient developed
severe cervical arthritis and could not lie flat, and one patient
had a neuropsychiatric illness during the screening phase.
The crossover study design allocated subjects with an in situ
TIPSS to randomly receive either a physiologic 500-nmol (220
mg folic acid equivalent) dose of 13C5-folic acid or 13C5-6S-5-
FormylTHF (Merck Eprova), with the label being carried by the
5 carbons of the glutamate moiety. Study days coincided with
the participant’s annual TIPSS surveillance checkup with
crossover dosing that occurred at the next annual checkup. After
an overnight fast, a routine TIPSS venogram was carried out by
experienced radiologists to confirm the patency of the TIPSS. A
catheter (65-cm 5Fr Beacon Tip Royal Flush Plus High Flow
Catheter; Cook Medical Europe Ltd) was placed in the portal
vein and flushed with 10 IU/mL heparin sodium solution
(Hepsal Wockhardt UK Ltd). The position of the portal catheter
was confirmed at the end of the procedure by using fluoroscopy.
A peripheral venous cannula was placed in a median cubital
fossa vein and flushed with a 0.9% sodium chloride solution.
Oral doses stored in a cold chain at 2208C were reconstituted
in 30 mL sterile water (,0.25 EU/mL per Medicines and
Healthcare Products Regulatory Agency guidelines), and timed
(postdose) portal (15, 25, 35, 45, 55, 65, and 85 min) and sys-
temic (30, 60, 90, 120, 150, 180, 210, and 240 min) venous
blood samples were taken. The time frame of measurements was
a result of limitations on the total volume of blood that could be
drawn as stipulated by the Ethics Committee and also to keep it
as reasonable as possible for the volunteers.
Sample analysis
All blood samples were collected in 5-mL lithium heparin
evacuated tubes (BD), which were held at 48C before plasma
preparation by using chilled centrifugation. Samples were stored
in light-protected Eppendorf Safe-Lock tubes (Eppendorf UK
Limited) at 2808C before analysis by using a high sensitivity
liquid chromatography–tandem mass spectrometry assay on the
basis of a method described previously (23). In brief, each
sample (5 mL) was analyzed by using an Agilent 1200 binary
HPLC (Agilent Technologies) coupled to an AB Sciex 4000
Qtrap triple-quadrupole mass spectrometer (AB Sciex UK
Limited). HPLC was achieved by using a binary gradient of
solvent A [MilliQ Water (VWR International Limited) plus 0.1%
formic acid] and solvent B (HPLC-grade acetonitrile plus 0.1%
formic acid) at a constant flow rate of 250 mL/min. Separation was
made by using a Phenomenex Kinetex 2.6-m C18 100 3 2.1-mm
FIGURE 1. Location of the TIPSS in the liver. TIPSS, transjugular intra-
hepatic porto systemic shunt.
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column (Phenomenex) maintained at 508C. Injection was made
at 2% B and held for 2.5 min, ramped to 10% B to 6 min, and
ramped to 43% B by 15 min. A 98% B column wash was ap-
plied until 23 min, and the column was equilibrated to initial
conditions for 10 min.
The mass spectrometer was operated in electrospray positive
mode tomonitor specific parent/fragment transitions for folate target
compounds as folic acid (442/295), 13C-folic acid (447/295),
5MeTHF (460/313), 13C-5MeTHF (465/313), 5-FormylTHF (474/
327), 13C-5FormylTHF (479/327), and methotrexate (455/308).
Optimized ionization and collision energies were tuned and
applied to each transition (not reported). Quantification was
applied with Analyst 1.5 software (AB Sciex) to integrate
detected peak areas relative to the methotrexate internal stan-
dard. Reproducibility (expressed as the CV) was as follows:
folic acid = 8%, 13C-folic acid = 14%, 5MeTHF = 10%, 13C-
5MeTHF = 7%, 5-FormylTHF = 13%, and 13C-5FormylTHF =
15%. Recovery was as follows: folic acid = 82%, 13C- folic acid =
94%, 5MeTHF= 77%, 13C-5MeTHF= 87%, 5-FormylTHF= 99%,
and 13C-5FormylTHF = 85%.
Statistical analysis
The percentage of folate in unmodified and modified forms in
the portal vein for each of the different oral dosing formulations,
at the initial 15-min postdosing time point was compared by using
a paired Student’s t test (Excel 2010; Microsoft Corp). The
percentage of folate in modified and unmodified forms between
different oral dosing formulations was compared by using an
unpaired (2-sample) Student’s t test. Although the sample size
was small, diagnostic checks suggested that the data were ap-
propriate for parametric statistical analysis methods. Data are
presented as means 6 SDs unless stated otherwise.
RESULTS
Six subjects (4 men and 2 women) participated in the study
between April 2009 and September 2011. Volunteer character-
istics are given in Table 1. The age of participants was 556 7 y,
and BMI (in kg/m2) was 33 6 10. The serum vitamin B-12
concentration was 555 6 186 ng/L, and the red blood cell folate
concentration was 698 6 523 nmol/L. Measures of liver disease
severity were monitored (eg, by using the Childs-Pugh Score
and Grade and MELD Score), and results indicated that study
participants had little or no ongoing liver injuries (data not
shown). Of 6 subjects that entered the study, all subjects com-
pleted the folic acid arm, but subjects 4 and 5 did not ingest the
labeled 5-FormylTHF dose because their annual TIPSS
checkups fell outside the time frame of the study. Therefore,
results are reported as n = 6 for folic acid and n = 4 for 5-
FormylTHF unless stated otherwise.
The comparison of portal venous plasma concentrations of
labeled folic acid and labeled 5-MTHF (the product of the
physiologic reduction and methylation of dietary folates) after
ingestion of the folic acid dose showed that unmetabolized la-
beled folic acid concentration rose significantly and more rapidly
than did labeled 5-MTHF concentrations (Figure 2A). At the
initial 15-min sampling time point, a consistent pattern was seen
across 5 participants (one volunteer’s 15-min sample did not
contain any detectable labeled folate) with 80 6 12% of labeled
folate in the hepatic portal vein after a dose of folic acid being
unmodified folic acid. This result was significantly higher (P ,
0.01) than the 20 6 12% for labeled 5-MTHF. The labeled folic
acid concentration peaked at w25 min (postdose), and steadily
declined to be approximately equal in concentration to the la-
beled 5-MTHF at 85 min. In contrast, the labeled 5-MTHF
concentration rose slowly from 1.2 6 4.2 nmol/L at 15 min to
a maximum of 3.7 6 6.5 nmol/L at 85 min. The appearance of
labeled folic acid was also observed in the systemic (peripheral)
circulation at each time point (Figure 2B).
In contrast, at the initial 15-min time point, the unmodified
form of labeled 5-FormylTHF was seen at extremely low con-
centrations in the portal circulation when subjects were given
the 5-FormylTHF dose (Figure 2C). A mean (6SD) 4 6 18%
of labeled folate in the hepatic portal vein was unmodified 5-
FormylTHF compared with 96 6 18% for labeled 5-MTHF
(P , 0.001). The labeled 5-FormylTHF concentration was very
low and had a maximum value at 15 min (0.8 6 0.4 nmol/L)
before steadily declining to w0.1 6 0.1 nmol/L at 85 min. In
contrast, the labeled 5-MTHF concentration was high and
peaked at 15 min with a mean (6SD) of 25.9 6 15.9 nmol/L
and declined steadily to 10.1 6 4.7 nmol/L at 85 min. Very little
of the unmodified form of 5-FormylTHF was observed in the
systemic plasma at any time point (Figure 2D).
When we compared between oral doses, the percentage of
total labeled folate that appeared as unmodified folic acid in the
hepatic portal vein was significantly greater (P , 0.0001) than
the percentage of total labeled folate that appeared as un-
modified 5-FormylTHF at each time point. In addition, at the
15-min time point, the mean concentration of labeled 5-MTHF
TABLE 1
Baseline characteristics of study participants at study enrollment1
Subject
identifier Sex Age
Etiology of
liver disease BMI
Plasma B-12
concentration
Red blood cell
folate concentration
y kg/m2 ng/L nmol/L
1 M 57 Nonalcoholic steatohepatitis 33 806 1679
2 M 56 Alcohol 42 576 888
3 M 61 Alcohol 27 336 326
4 F 59 Alcohol 26 569 342
5 M 44 Alcohol 47 349 419
6 F 53 Budd-Chiari 23 692 535
1All participants were clinically stable, and there was no significant change in any variable, and no deterioration in any
variable was seen between annual assessments.
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(1.2 6 1.0 nmol/L) derived from folic acid was significantly
lower (P , 0.01) than the mean concentration of labeled 5-
MTHF (25.9 6 15.9 nmol/L) derived from 5-FormylTHF.
The AUC of the data presented in Figure 2, A and C, can be
used as a surrogate measure for the quantity of labeled folate
entering the portal blood systems from folic acid and 5-
FormylTHF doses, respectively. The AUCwas estimated by using
the trapezoidal method (or rule). In brief, the area bounded by the
y axis, x axis, and curve was divided into rectangles, and the areas
of those rectangles (base 3 height) were calculated, and each
rectangle area was summed to arrive at the estimate for the AUC.
From Figure 2A, it can be calculated that, for the oral dose of
folic acid, the AUCFolicdose of total labeled folate (folic acid + 5-
MTHF) was 597 nmol $ min21 $ L21. From Figure 2C, it can be
calculated that, for the oral dose of 5-FormylTHF, the AUCFormyldose
of total labeled folate (5-FormylTHF + 5-MTHF) was 1102 nmol $
min21 $ L21. The ratio of the 2 (AUCFormyldose:AUCFolicdose)
was 1.8. The results indicated that almost twice as much folate
from the labeled 5-FormylTHF dose crossed into the hepatic
portal vein from mucosal cells in the first 85 min (postdose)
compared with the amount of folate derived from the labeled
folic acid dose.
In addition, the maximum concentration over the timeframe of
the experiment of labeled 5-MTHF in the hepatic portal vein was
seen to occur 85 min after the ingestion of the folic acid dose
(Figure 2A) compared with that just 15 min after the dose of 5-
FormylTHF (Figure 2C). The magnitude of these maximum
concentrations of labeled 5-MTHF were significantly different
[3.7 6 1.7 nmol/L (after the folic acid dose) compared with
25.96 15.9 nmol/L (after the 5-FormylTHF dose); P, 0.001].
DISCUSSION
In this study, it has been shown that the majority of a physi-
ologic oral dose of folic acid passes into the portal venous cir-
culation in an unmodified form. In contrast, the oral dose of the
dietary folate 5-FormylTHF was nearly all converted and appeared
in the portal venous circulation almost entirely as 5-MTHF,
which is an observation that confirmed normal gut wall function
in terms of both gut permeability and the folate methylation
capacity.
These findings fundamentally challenge the model of folic
acid biotransformation when applied specifically to humans.
The reason for the very limited reduction and subsequent
methylation of folic acid to 5-MTHF in mucosal cells was
probably the inadequate activity of dihydrofolate reductase
(DHFR) in the enterocyte, which made a reduction of folic acid
the rate-limiting step. A recent study showed that the human
liver has a low and highly variable DHFR activity (24). If this
finding was replicated in human mucosal cells, it would explain
FIGURE 2. A: Mean (6SEM) concentrations of labeled folic acid (circles) and labeled 5-MTHF (squares) in the hepatic portal venous circulation after the
ingestion of a labeled folic acid dose (n = 6). At time = 15 min, there was a significantly (P , 0.01) higher percentage of labeled folic acid than labeled 5-
MTHF. B: Mean (6SEM) concentrations of labeled folic acid (circles) and labeled 5-MTHF (squares) in systemic plasma after the ingestion of a labeled folic
acid dose (n = 6). C: Mean (6SEM) concentrations of labeled 5-FormylTHF (diamonds) and labeled 5-MTHF (squares) in the hepatic portal venous
circulation after the ingestion of a labeled formyl dose (n = 4). At time = 15 min, there was a significantly (P , 0.001) higher percentage of labeled 5-
MTHF than of labeled 5-FormylTHF. D: Mean (6SEM) concentrations of labeled 5-FormylTHF (diamonds) and labeled 5-MTHF (squares) in systemic
plasma after the ingestion of a labeled formyl dose (n = 4). Note differences in study durations for portal (A and C) and systemic (B and D) elements of the
study. Also note differences in y-axis scales between panels. 5-FormylTHF, 5-formyltetrahydrofolic acid; 5-MTHF, 5-methyltetrahydrofolic acid.
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the current study observation of unmodified folic acid in the
portal vein.
The most obvious reason for the discrepancy between findings
in this study and those in previous studies that showed the gut
reduction and methylation of folic acid was the use of rodent
models (most typically rat) and human cell lines. Both of these
approaches have inherent weaknesses. Rats have significantly
higher concentrations of DHFR than do humans (24), which
make rats a poor model for human folic acid metabolism. Human
cell lines, grown in vitro, also exhibit elevated concentrations of
DHFR activity compared with that of human tumors or cells
obtained in situ, potentially as a consequence of the traditional
use of high concentrations of folic acid in tissue culture medium
(25).
Findings in this study confirmed and extended those of earlier
human studies published in the 1960s and 1970s (26, 27). These
articles were criticized for administering large, nonphysiologic
doses of folic acid and were largely disregarded. However, it was
a pertinent finding that no dose-derived 5-MTHF was initially
detected in the hepatic portal vein, albeit one overlooked by later
researchers.
Another surprising finding from the current study was the
apparent lower absorption of folic acid compared with 5-
FormylTHF as evidenced from an examination of Figure 2, A
and C, and the computation of respective AUCs of the total
labeled folate that appeared in the portal vein during the first
85 min postdose. Nearly 2 times more labeled folate appeared to
cross the gut wall from the ingestion of the 5-FormylTHF dose
compared with that from the folic acid dose. At face value, this
finding appears to contradict previous studies in ileostomy
subjects that showed that single 453-nmol doses of 13C5-folic
acid (close to the 500-nmol dose in the current study) were
extensively absorbed (w90%) by the gut mucosa (28). Also,
daily supplementation with either folic acid or 5-MTHF has
been equally effective in raising red blood cell folate concen-
trations to the same extent (29).
A possible explanation for the apparent discrepancy between the
low absorption of folic acid as calculated from the AUC of total
labeled folate that initially appeared in the portal vein in the current
study and that calculated from ileostomy subjects can be ascer-
tained by examining the proposed mechanism of folate transport
into and out of the enterocytes (shown schematically in Figure 3).
First, both reduced tetrahydrofolates (eg, 5-FormylTHF) and folic
acid are taken up by mucosal cells with a similar affinity by the
proton-coupled folate transporter (PCFT) (16). Once inside the
mucosa, the cell machinery attempts to metabolize the newly
absorbed folate to 5-MTHF. In the case of folic acid, this me-
tabolization appears to be extremely limited. Finally, the un-
metabolized and metabolized folate will be transported out of the
cell into the hepatic portal vein. The mechanism of folate trans-
port out of the mucosal cells is not clear, but multidrug resistance
proteins (MRPs) are expressed at the basolateral membrane, and
it is thought that they have a key role to play, especially that of
MRP3 (16). However, MRP3 transports folic acid with a much-
lower efficiency than the reduced tetrahydrofolate form (30). This
lack of efficiency, rather than the different extent of absorption,
might explain the observation that approximately twice as
much labeled folate was shown in the portal blood after the 5-
FormylTHF dose than the folic acid dose during the first
85 min postdose.
In this study, all subjects had inactive liver disease and normal
liver synthetic function and all were abstinent from alcohol. The
major confounding factor, ie, that of increased gut permeability,
was eliminated both by prescreening for gut permeability (data not
shown) and determining, as part of the study, the complete con-
version of the dose of natural folate (5-FormylTHF). The essential
absence of 5-FormylTHF detected in the hepatic portal vein
following a dose of 5-FormylTHF implies that the passage of all
labeled folate was through the enterocytes and not between
enterocytes. Therefore, the pattern of data that is shown in Figure 2,
A and C, generated from the analysis of the hepatic portal vein
blood samples should reflect that shown in the general population.
More caution needs to be applied to systemic circulation data
(Figure 2, B and D) because of the capacity for periportal
shunting effects in TIPSS patients. The subsequent appearance of
unmodified folic acid in the peripheral circulation reflected the
medical design of the TIPSS; significant quantities of blood from
the hepatic portal vein bypassed the liver via a shunt to the hepatic
vein (and then onto the inferior vena cava as shown in Figure 1).
When single physiologic 634-nmol (280-mg) doses of stable-
isotope–labeled folic acid have been given to subjects without
a TIPSS, who were neither exposed to mandatory fortification
nor self-supplementation, no unmetabolized labeled folic acid
was seen in the systemic circulation, only labeled 5-MTHF (22).
However, note that the use of a combined HPLC and microbi-
ological assay, subnanomolar concentrations were shown in 1 of
4 subjects given 5 consecutive doses of 200 mg (453 nmol) folic
acid at 90-min intervals (31).
If folic acid (when given as a single physiologic dose ,634
nmol) is mainly transferred to the hepatic portal vein un-
metabolized, it may be concluded that, under normal experi-
mental conditions, folic acid that enters the hepatic portal vein
must be almost completely removed by the liver during its first
pass and, because of its low DHFR activity, only slowly bio-
transformed to 5-MTHF before either entering the systemic
circulation in a visibly attenuated response or being excreted in
the bile. It is also possible that some folic acid may be converted
FIGURE 3. Proposed folate absorption from the gut lumen, metabolism
in mucosal cells, and transport out into the hepatic portal vein. DHFR,
dihydrofolate reductase; MRP3, multidrug resistance protein 3; PCFT,
proton-coupled folate transporter; THF, tetrahydrofolate; 5-FormylTHF, 5-
formyltetrahydrofolic acid; 5-MTHF, 5-methyltetrahydrofolic acid.
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to polyglutamate forms and stored in the liver. Whatever the
initial fate of the folic acid, the human liver has been shown to
have not only a low but highly variable DHFR activity (24).
Therefore, chronic exposure to folic acid in physiologic doses
(as would be the case with mandatory fortification) may induce
saturation and explain the observed systemic circulation of un-
metabolized folic acid (8).
We acknowledge that the study was limited in terms of the
number of subjects studied. However, this limitation reflects the
unique and rare nature of the population in whom the study could
be performed (ie, hepatologically stable patients with a TIPSS in
situ). Despite the limitation of the study population size, we
believe that the study of this unique group of people has allowed
important insights into the physiology of folate absorption in
humans that could not have been generated in any other ex-
perimental system.
In conclusion, a low enzyme activity of DHFR may com-
promise both mucosal and liver biotransformation of folic acid in
humans. For dietary supplements, it is suggested that folic acid
could be replaced with 6S-5-MTHF (the normal systemically
circulating folate form), the multiple advantages of which have
been noted previously (32). The Food and Drug Administration in
the United States and the European Food Standards Agency have
already approved products containing a 5-MTHF calcium salt
(Metafolin; Merck & Cie) and a 5-MTHF glucosamine salt
(Quatrefolic; Gnosis).
It is also suggested that effort is made to microencapsulate 5-
MTHF so that losses from manufacture, the use in voluntary
fortified foods (eg, breakfast cereals), and the subsequent pro-
cessing (eg, heat) of products are minimized (33). If this effort
can be accomplished successfully, consideration could be given
to replacing folic acid with 5-MTHF in countries that have
mandatory programs of flour fortification.
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